NCT02142218No Longer Available不适用
Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)
Bristol-Myers Squibb21 个研究点 分布在 2 个国家开始时间: 2014年6月最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 21
研究概览
简要总结
The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ECOG Performance Status of 0-1
- •Histologically confirmed malignant melanoma
- •Progressed on or after treatment with an anti-CTLA4
排除标准
- •Active brain metastases
- •Life Expectancy <6 weeks
- •Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy
- •Subjects with autoimmune disease
研究者
研究点 (21)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenSquamous Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung CancerNCT02475382Bristol-Myers Squibb
No Longer Available
不适用
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaMalignant MelanomaNCT02186249Bristol-Myers Squibb
尚未招募
不适用
EXPANDED ACCESS PROGRAM WITH NIVOLUMAB FOR SUBJECTS WITH HISTOLOGICALLY CONFIRMED STAGE III (UNRESECTABLE) OR STAGE IV MELANOMA PROGRESSING POST PRIOR SYSTEMIC TREATMENT CONTAINING AN ANT-CTLA-4 MONOCLONAL ANTIBODY.-C439 Malignant melanoma of skin, unspecifiedMalignant melanoma of skin, unspecifiedC439PER-012-15BRISTOL MYERS SQUIBB COMPANY,
No Longer Available
不适用
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)Extranodal NK/T-cell LymphomaNCT05131438EQRx International, Inc.
招募中
Unknown
Expanded Access Program with Nivolumab (ONO-4538) for malignant non-pleural mesothelioma (VIOLA)Malignant MesotheliomaNivolumabMesotheliomaJPRN-jRCT2051220186Kijima Takashi15